Provided by Tiger Trade Technology Pte. Ltd.

COYA THERAPEUTICS INC

4.82
-0.0100-0.21%
Post-market: 4.870.0496+1.03%17:04 EDT
Volume:118.69K
Turnover:565.12K
Market Cap:113.02M
PE:-4.15
High:4.87
Open:4.83
Low:4.64
Close:4.83
52wk High:7.75
52wk Low:3.71
Shares:23.45M
Float Shares:17.82M
Volume Ratio:1.44
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1601
EPS(LYR):-1.2700
ROE:-51.31%
ROA:-27.57%
PB:2.31
PE(LYR):-3.80

Loading ...

Coya Therapeutics presents ALSTARS Phase 2 trial design at ALS Drug Development Summit

Reuters
·
May 27

Analysts Offer Insights on Healthcare Companies: Coya Therapeutics, Inc. (COYA), Beta Bionics, Inc. (BBNX) and Arvinas Holding Company (ARVN)

TIPRANKS
·
May 22

Coya Therapeutics, Inc. (COYA) Gets a Buy from Lake Street

TIPRANKS
·
May 13

Coya Therapeutics announces annual shareholder meeting

Reuters
·
May 13

Coya Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Coya Therapeutics: Entered Into Sales Agreement, May Offer and Sell From Time to Time Shares of Co's Common Stock for up to $30 Mln

THOMSON REUTERS
·
May 12

Coya Therapeutics enters at-the-market equity sales agreement for up to $30 million stock offering

Reuters
·
May 12

Coya Therapeutics granted FDA Fast Track Designation for COYA 302

TIPRANKS
·
May 12

Coya Therapeutics Q1 FY26 net loss narrows to $7.2 million

Reuters
·
May 12

Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

THOMSON REUTERS
·
May 12

Coya Therapeutics Q1 Net Income USD -7.2 Million

THOMSON REUTERS
·
May 12

Coya Therapeutics wins FDA fast track status for ALS drug COYA 302

Reuters
·
May 12

Coya Therapeutics Inc - Conducting Phase 2 Alstars Trial of Coya 302 for ALS

THOMSON REUTERS
·
May 12

Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for Coya 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

THOMSON REUTERS
·
May 12

Coya Therapeutics Inc expected to post a loss of 41 cents a share - Earnings Preview

Reuters
·
May 08

Coya Therapeutics director Mark H. Pavao files initial beneficial ownership statement

Reuters
·
Apr 10

Coya study links ALS inflammation biomarkers to survival, supporting COYA 302 rationale

Reuters
·
Apr 09

Coya Therapeutics names Mark Pavao independent director as founder Howard Berman exits board

Reuters
·
Apr 02

Coya Therapeutics Inc - Howard Berman Steps Down as Executive Chairman and Director

THOMSON REUTERS
·
Apr 02

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

THOMSON REUTERS
·
Apr 02